Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY
Stroke · 2023
DOI: 10.1161/strokeaha.122.041628 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2023. Verfasst von Daniel Caldeira und 2 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Cardiologia, Hospital Universitário de Santa Maria - CHULN, Portugal (D.C., P.A.d.S., F.J.P.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Craniocerebral Trauma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Themen: Sturzprophylaxe
Abstract (Originalsprache)
Background
Falls are always a concern regarding the balance of risk/benefit in patients with atrial fibrillation treated with anticoagulants. In this analysis, we aimed to evaluate the outcomes of patients that had a fall/head injury reported in the RE-LY clinical trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) and to explore the safety of dabigatran (a nonvitamin K antagonist oral anticoagulant).
Methods
We performed a post hoc retrospective analysis of intracranial hemorrhage and major bleeding outcomes in the RE-LY trial with 18 113 individuals with atrial fibrillation, according to the status occurrence of falls (or head injury) reported as adverse events. Multivariate Cox regression models were used to provide adjusted hazard ratio (HR) and 95% CI.
Results
In the study, 974 falls or head injury events were reported among 716 patients (4%). These patients were older and had more frequently comorbidities such as diabetes, previous stroke, or coronary artery disease. Patients with fall had a higher risk of major bleeding (HR, 2.41 [95% CI, 1.90–3.05]), intracranial hemorrhage (HR, 1.69 [95% CI, 1.35–2.13]), and mortality (HR, 3.91 [95% CI, 2.51–6.10]) compared to those who did not have reported falls or head injury. Among patients who had falls, those allocated to dabigatran showed a lower intracranial hemorrhage risk (HR, 0.42 [95% CI, 0.18–0.98]) compared with warfarin.
Conclusions
In this population, the risk of falls is important and confers a worse prognosis, increasing intracranial hemorrhage, and major bleeding. Patients who fell and were under dabigatran was associated with lower intracranial hemorrhage risk than those anticoagulated with warfarin, but the analysis was merely exploratory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Serviço de Cardiologia, Hospital Universitário de Santa Maria - CHULN, Portugal (D.C., P.A.d.S., F.J.P.).
- Centro Cardiovascular da Universidade de Lisboa - (CCUL@RISE), CAML, CEMBE, Faculdade de Medicina, Universidade de Lisboa, Portugal (D.C., P.A.d.S., F.J.P.).
- Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina da Universidade de Lisboa, Portugal (D.C.).
ORCID-Profile: Daniel Caldeira, Fausto J Pinto
Zitieren
APA
Caldeira, D., Alves da Silva, P., & Pinto, F. J. (2023). Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY. Stroke. https://doi.org/10.1161/strokeaha.122.041628
Vancouver
Caldeira D, Alves da Silva P, Pinto FJ. Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY. Stroke. 2023. doi:10.1161/strokeaha.122.041628
BibTeX
@article{Caldeira2023,
author = {Caldeira, Daniel and Alves da Silva, Pedro and Pinto, Fausto J},
title = {Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY},
journal = {Stroke},
year = {2023},
doi = {10.1161/strokeaha.122.041628}
}
EUVIMED